Last edition
News about
FDA Approves Novartis's Rhapsido as First Oral BTK Inhibitor for Chronic Spontaneous Urticaria
The US Food and Drug Administration (FDA) has approved Novartis’ Rhapsido (remibrutinib) as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who continue to experience symptoms despite H1 antihistamine therapy.
Virupaksha Organics Files Draft Papers with SEBI for INR 740 Crore IPO
Virupaksha Organics, an R&D-driven Indian pharmaceutical company specialising in active pharmaceutical ingredients (APIs) and intermediates, has filed draft papers with India’s capital markets regulator, SEBI, to raise INR 740 crore through an initial public offering (IPO).
Bristol Myers and Takeda Join AI Consortium to Accelerate Drug Discovery
Bristol Myers Squibb and Takeda Pharmaceuticals have agreed to collaborate in a new AI-driven drug discovery initiative, pooling proprietary molecular structure datasets to train an advanced AI model known as OpenFold3.
Testo Saveris to Showcase Comprehensive Pharma Monitoring System at CPHI 2025
Instrumentation and measurement specialist Testo Saveris will present its fully automated and comprehensive monitoring system, testo Saveris 1 at CPHI 2025 in Frankfurt, taking place from 28–30 October.
Parexel Announces AI Partnership with Weave Bio to Accelerate Regulatory Submission Processes
The collaboration leverages Parexel's proven regulatory expertise and Weave Bio's AI-native platform, aims to speed up market introduction of new therapies.
Novavax, Sanofi Deepen Partnership to Include Matrix-M in Pandemic Influenza Vaccine Programme
The expanded partnership allows Sanofi to use Novavax’s Matrix-M adjuvant in its pandemic influenza vaccine candidate programme.
Artemis Acquires Millrock Technology
Under Artemis' ownership, Millrock will continue to operate as an independent company from its facility in Kingston, New York, serving a global customer base.
AbbVie has begun a USD 70 million expansion of its AbbVie Bioresearch Center (ABC) in Worcester, Massachusetts, and broken ground on a new North Chicago Active Pharmaceutical Ingredient (API) manufacturing facility.
Pfizer signs Agreement with US Government to Lower Drug Costs for American Patients
Pfizer has voluntarily agreed to implement measures designed to ensure Americans receive comparable drug prices to those available in other developed countries and pricing newly launched medicines at parity with other key developed markets.
Promocell Enters GMP Field with Launch of Custom Cell Culture Media Services
PromoCell GmbH has announced its entry into the Good Manufacturing Practice (GMP) field with the launch of custom cell culture media services designed specifically for cell-based therapy and regenerative medicine.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy